2025
$4.01
▼
Recomputed on current basis (prior figure of $2.94 did not strip working capital). OE = CFO - working-capital cash movement - SBC - maintenance capex, continuing operations (OxyChem in discontinued operations). CFO=$9,606M; WC cash effect=$(1,067)M (trade receivables +252, inventories +12, JV receivables/other current assets -62, payables and accrued liabilities -964, income taxes -305), so CFO ex-WC=$10,673M; SBC=$234M; capex=$6,427M treated entirely as maintenance (oil and gas revenue moves with price, not volume, so the revenue-based growth-capex formula would mistake price for growth; judgement applied to every year); OE=$4,012M; diluted shares=1,000.1M; OE/sh=$4.01. Reconciliation: income from continuing ops $2,107M + DD&A $7,533M + deferred tax $127M + other non-cash $420M + impairments $21M - gains $263M + equity-investee losses $619M + dry hole $109M = $10,673M = CFO ex-WC (0% gap). Memo: cash interest paid $1,250M, so pre-lender business cash flow = $5,262M or $5.26/sh. Pre-preferred ($679M dividends were a senior claim). Source: FY2025 10-K, accession 0001628280-26-009059.
2024
$4.10
▼
Recomputed on current basis (prior figure of $4.18 did not strip working capital). OE = CFO - working-capital cash movement - SBC - maintenance capex, continuing operations as restated for the OxyChem sale. CFO=$10,519M; WC cash effect=$+75M (receivables -116, inventories -27, JV receivables/other current assets +286, payables/accrued -540, income taxes +472), so CFO ex-WC=$10,444M; SBC=$213M; capex=$6,263M all treated as maintenance (price-driven revenue; see FY2025 note); OE=$3,968M; diluted shares=967.1M; OE/sh=$4.10. Reconciliation: income from continuing ops $2,866M + DD&A $6,951M + deferred tax $(265)M + other non-cash $454M + impairments $355M + losses on sales $60M + equity earnings $(83)M + dry hole $106M = $10,444M = CFO ex-WC (0% gap). Memo: cash interest paid $1,052M, so pre-lender business cash flow = $5,020M or $5.19/sh. Excludes the $8.8B cash CrownRock purchase (acquisition, not maintenance). Pre-preferred ($679M dividends). WTI averaged $75.72/Bbl. Source: FY2025 10-K, accession 0001628280-26-009059.
2023
$4.37
▼
Recomputed on current basis (prior figure of $4.51 did not strip working capital). OE = CFO - working-capital cash movement - SBC - maintenance capex, continuing operations as restated for the OxyChem sale. CFO=$10,235M; WC cash effect=$+140M (receivables +931, inventories -84, JV receivables/other current assets -350, payables/accrued -423, income taxes +66), so CFO ex-WC=$10,095M; SBC=$203M; capex=$5,696M all treated as maintenance (price-driven revenue; see FY2025 note); OE=$4,196M; diluted shares=960.9M; OE/sh=$4.37. Reconciliation: income from continuing ops $3,332M + DD&A $6,449M + deferred tax $54M + other non-cash $133M + impairments $209M - gains $522M + equity losses $141M + dry hole $299M = $10,095M = CFO ex-WC (0% gap). Memo: cash interest paid $1,017M, so pre-lender business cash flow = $5,213M or $5.43/sh. Pre-preferred ($923M of preferred dividends and redemption premiums). Source: FY2025 10-K, accession 0001628280-26-009059.
2022
$13.35
▼
Recomputed on current basis (prior figure of $12.03 did not strip working capital). OE = CFO - working-capital cash movement - SBC - maintenance capex. INCLUDES OxyChem (pre-sale presentation, not restated; not comparable to FY2023+ continuing-operations years) and is a cycle-peak year (WTI ~$94). CFO from continuing operations=$16,810M; WC cash effect=$(1,325)M (receivables -97, inventories -230, other current assets -335, payables/accrued -478, income taxes -185), so CFO ex-WC=$18,135M; SBC=$258M; capex=$4,497M all treated as maintenance (price-driven revenue; see FY2025 note); OE=$13,380M; diluted shares=1,002.0M; OE/sh=$13.35. Pre-preferred ($800M dividends). Source: FY2022 10-K, accession 0000797468-23-000011.
2021
$8.89
▼
Recomputed on current basis (prior figure of $7.59 used total CFO and did not strip working capital). OE = CFO - working-capital cash movement - SBC - maintenance capex. INCLUDES OxyChem (pre-sale presentation, not restated; not comparable to FY2023+ continuing-operations years); capex was cyclically depressed after 2020. CFO from continuing operations=$10,253M; WC cash effect=$(1,426)M (receivables -2,086, inventories -86, other current assets -119, payables/accrued +865, income taxes 0), so CFO ex-WC=$11,679M; SBC=$287M; capex=$2,870M all treated as maintenance (price-driven revenue; see FY2025 note); OE=$8,522M; diluted shares=958.8M; OE/sh=$8.89. Pre-preferred. Source: FY2022 10-K, accession 0000797468-23-000011 (2021 column); SBC from FY2021 10-K accession 0000797468-22-000008.
2020
$2.59
▼
OE = CFO - working-capital cash movement - SBC - maintenance capex. Trough year (WTI averaged $39.40/Bbl). INCLUDES OxyChem and the pre-CrownRock asset base (pre-sale presentation, not restated). CFO from continuing operations=$3,842M; WC cash effect=$(1,278)M (receivables +2,062, inventories -484, other current assets +350, payables/accrued -3,228, income taxes +22), so CFO ex-WC=$5,120M; SBC=$202M; capex=$2,535M all treated as maintenance (price-driven revenue; see FY2025 note); OE=$2,383M; diluted shares=918.7M; OE/sh=$2.59. Memo: cash interest paid $1,521M. Source: FY2022 10-K accession 0000797468-23-000011 (2020 column) and FY2020 10-K accession 0000797468-21-000009.
2019
-$0.33
▼
OE = CFO - working-capital cash movement - SBC - maintenance capex. Anadarko acquisition year (closed Aug 2019): capex includes Anadarko from closing while weighted shares reflect only part-year issuance; not representative. INCLUDES OxyChem. CFO from continuing operations=$7,336M; WC cash effect=$+1,027M (receivables +401, inventories +78, other current assets +170, payables/accrued +358, income taxes +20), so CFO ex-WC=$6,309M; SBC=$208M; capex=$6,367M all treated as maintenance (price-driven revenue; see FY2025 note); OE=$(266)M; diluted shares=809.5M; OE/sh=$(0.33). Memo: cash interest paid $912M. Source: FY2020 10-K accession 0000797468-21-000009 (2019 column).
2018
$3.98
▼
OE = CFO - working-capital cash movement - SBC - maintenance capex. Pre-Anadarko company including OxyChem. CFO from continuing operations=$7,669M; WC cash effect=$(521)M (receivables +955, inventories -108, other current assets +94, payables/accrued -1,500, income taxes +38; 'other operating, net' of $77M excluded), so CFO ex-WC=$8,190M; SBC=$180M; capex=$4,975M all treated as maintenance (price-driven revenue; see FY2025 note); OE=$3,035M; diluted shares=763.3M; OE/sh=$3.98. Memo: cash interest paid $383M. Source: FY2020 10-K accession 0000797468-21-000009 (2018 column) and FY2018 10-K accession 0000797468-19-000004.
Owner's earnings per share by fiscal year, most recent first. Tap a row to see how that figure was calculated, including the source filing.